Free US stock correlation to major indices and sector benchmarks for performance attribution analysis. We help you understand how your portfolio moves relative to broader market benchmarks.
Terns Pharmaceuticals Inc. (TERN), a clinical-stage biopharmaceutical company focused on developing novel treatments for oncology and rare endocrine diseases, is trading at $52.72 as of 2026-04-02, posting a marginal 0.13% intraday decline. This analysis breaks down key near-term technical levels for TERN, recent sector trends impacting biotech trading, volume dynamics, and potential price scenarios for market participants monitoring the stock. With no recent earnings data available for the comp
Can Terns Pharmaceuticals (TERN) Stock Beat Estimates | Price at $52.72, Down 0.13% - Earnings Season
TERN - Stock Analysis
3826 Comments
824 Likes
1
{用户名称}
{用户等级}
2 hours ago
{协议答案}
👍 230
Reply
2
{用户名称}
{用户等级}
5 hours ago
{协议答案}
👍 240
Reply
3
{用户名称}
{用户等级}
1 day ago
{协议答案}
👍 12
Reply
4
{用户名称}
{用户等级}
1 day ago
{协议答案}
👍 84
Reply
5
{用户名称}
{用户等级}
2 days ago
{协议答案}
👍 284
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.